Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

UPDATE: Credit Suisse Upgrades Bancolombia SA as Valuation Seems Attractive

Share:

In a report published Friday, Credit Suisse analyst Marcelo Telles upgraded the rating on Bancolombia SA (NYSE: CIB) from Neutral to Outperform, but lowered the price target from $69.00 to $61.00.

In the report, Credit Suisse noted, “Following our multi-year negative stance on Bancolombia, we decided to raise CIB from Neutral to Outperform as valuation seems attractive even after we incorporate the upcoming capital increase as well as HSBC acquisition, on the back of recovery in margins and better asset quality. Our new TP at US$61/ADR (US$69 previously) offers attractive upside potential of 24%. We forecast EPADR of US$4.34 for 14' and US$4.78 for 15' (ex-goodwill), implying improvement in ROE to 15.1% from 13.5% in 13'.”

Bancolombia SA closed on Thursday at $49.34.

Latest Ratings for CIB

DateFirmActionFromTo
Apr 2019DowngradesNeutralUnderperform
Apr 2019UpgradesNeutralBuy
Nov 2018DowngradesHoldUnderperform

View More Analyst Ratings for CIB
View the Latest Analyst Ratings

Posted-In: Credit Suisse Marcelo TellesAnalyst Color Upgrades Analyst Ratings

 

Related Articles (CIB)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
HELEMaintains160.0
JWNMaintains32.0
DYMaintains64.0
PSTGMaintains18.0
TJXMaintains56.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome

UPDATE: Credit Suisse Downgrades Performant Financial as Litany of Issues Cloud Outlook